Targeting STEAP1 as an anticancer strategy

Although the six-transmembrane epithelial antigen of prostate 1 (STEAP1) was first identified in advanced prostate cancer, its overexpression is recognized in multiple types of cancer and associated with a poor prognosis. STEAP1 is now drawing attention as a promising therapeutic target because of i...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2023-10, Vol.13, p.1285661-1285661
Main Authors: Nakamura, Hajime, Arihara, Yohei, Takada, Kohichi
Format: Article
Language:English
Subjects:
antibody therapy
anticancer strategies
cancer vaccine
CAR-T therapy
Oncology
STEAP1
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although the six-transmembrane epithelial antigen of prostate 1 (STEAP1) was first identified in advanced prostate cancer, its overexpression is recognized in multiple types of cancer and associated with a poor prognosis. STEAP1 is now drawing attention as a promising therapeutic target because of its tumor specificity and membrane-bound localization. The clinical efficacy of an antibody-drug conjugate targeting STEAP1 in metastatic, castration-resistant, prostate cancer was demonstrated in a phase 1 trial. Furthermore, growing evidence suggests that STEAP1 is an attractive target for immunotherapies such as chimeric antigen receptor-T cell therapy. In this review, we summarize the oncogenic functions of STEAP1 by cancer type. This review also provides new insights into the development of new anticancer strategies targeting STEAP1.
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2023.1285661